Finder makes money from featured partners, but editorial opinions are our own.

How to buy Australian Clinical Labs (ACL) shares in Australia

Learn how to easily invest in Australian Clinical Labs shares.

Australian Clinical Labs is a diagnostics & research business based in Australia. Australian Clinical Labs shares (ACL) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Australian Clinical Labs has a trailing 12-month revenue of around $697.1 million. If you're looking to buy shares, check out the steps below.

How to buy shares in Australian Clinical Labs

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for Australian Clinical Labs. Find the share by name or ticker symbol: ACL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Australian Clinical Labs reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check on your investment. Congratulations, you own a part of Australian Clinical Labs. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

Australian Clinical Labs stock price (ASX:ACL)

Use our graph to track the performance of ACL stocks over time.

Australian Clinical Labs shares at a glance

Information last updated 2023-12-04.
52-week range$2.47 - $3.7053
50-day moving average $2.6916
200-day moving average $3.1766
Target price$3.58
PE ratio 14.25
Dividend yield $0.14 (5.36%)
Earnings per share (TTM) $0.18

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
1 - 6 of 6
Name Product Standard brokerage fee Inactivity fee Asset class
Finder AwardExclusive
US$10 per month if there’s been no log-in for 12 months
ASX shares, Global shares, US shares, ETFs
CFD service. Capital at risk.
Finder exclusive: Get 12 months of investment tracking app Delta PRO for free when you fund your eToro account (T&Cs apply).
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
Finder Award
IG Share Trading
ASX shares, Global shares, US shares, UK shares, ETFs
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian and international shares, plus get access to 24-hour customer support.
Moomoo Share Trading
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get an additional 30 days on top of the regular brokerage-free period for new accounts. T&Cs apply.
Trade shares on the ASX, the US markets and buy ETFs with Moomoo. Plus join a community over 20 million investors.
CMC Invest
Finder Award
CMC Invest
ASX shares, Global shares, Options trading, US shares, mFunds, ETFs
$0 brokerage on global shares including US, UK and Japan markets.
Trade up to 35,000 products, including shares, crypto, ETFs and managed funds, with access to 15 major global and Australian stock exchanges. Plus, buy Aussie shares for $0 brokerage up to $1,000. (Limited to one buy order per stock per trading day).
ASX shares, Options trading, US shares, ETFs
Earn US$100 in cash vouchers when you fund your new account and maintain a minimum balance of US$2,000 by Dec 29 until March 31, 2024. Plus, earn up to 5.3% p.a. yield on your US cash account (T&Cs apply).
Trade ASX and US stocks and US options, plus gain access to inbuilt news platforms and educational resources. You can also start trading for less with fractional shares.
Tiger Brokers
Tiger Brokers
ASX shares, Global shares, US shares, ETFs
Finder exclusive: Get 10 brokerage-free trades for the US or ASX market for the first 180 days and US$50 fractional shares when you deposit at least US$500. Plus, all new customers get 1 free trade per month for the first 12 months (T&Cs apply).
Get one brokerage-free trade per month for the first 12 months for US or ASX markets. T&Cs apply.

Is it a good time to buy Australian Clinical Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Australian Clinical Labs price performance over time

Historical closes compared with the last close of A$2.87

1 week (2023-11-30) 9.54%
1 month (2023-11-10) 7.49%
3 months (2023-09-08) -4.65%
6 months (2023-06-09) -14.07%
1 year (2022-12-09) -7.42%
2 years (2021-12-10) -38.01%

Is Australian Clinical Labs under- or over-valued?

Valuing Australian Clinical Labs stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Australian Clinical Labs's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Australian Clinical Labs's P/E ratio

Australian Clinical Labs's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Australian Clinical Labs shares trade at around 14x recent earnings.

That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Australian Clinical Labs's EBITDA

Australian Clinical Labs's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $78.5 million (£0.0 million).

The EBITDA is a measure of a Australian Clinical Labs's overall financial performance and is widely used to measure stock profitability.

Australian Clinical Labs financials

Revenue TTM $697.1 million
Operating margin TTM 8.69%
Gross profit TTM $250.4 million
Return on assets TTM 6.63%
Return on equity TTM 17.79%
Profit margin 5.15%
Book value 0.86
Market capitalisation $526.8 million

TTM: trailing 12 months

Australian Clinical Labs share dividends

Dividend payout ratio: 107.69% of net profits

Recently Australian Clinical Labs has paid out, on average, around 107.69% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 5.36% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Australian Clinical Labs shareholders could enjoy a 5.36% return on their shares, in the form of dividend payments. In Australian Clinical Labs's case, that would currently equate to about A$0.14 per share.

Australian Clinical Labs's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

The latest dividend was paid out to all shareholders who bought their shares by 14 September 2023 (the "ex-dividend date").

Australian Clinical Labs share price volatility

Over the last 12 months, Australian Clinical Labs's shares have ranged in value from as little as $2.47 up to $3.7053. A popular way to gauge a stock's volatility is its "beta".

ACL.AU volatility(beta: 1.15)Avg. volatility(beta: 1.00)LowHigh

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Australian Clinical Labs's is 1.153. This would suggest that Australian Clinical Labs's shares are a little bit more volatile than the average for this exchange and represent, relatively speaking, a slightly higher risk (but potentially also market-beating returns).

Australian Clinical Labs overview

Australian Clinical Labs Limited provides pathology services in Australia. The company offers range of services, which include routine pathology test, advanced molecular genetics testing, harmony NIPT and first trimester screening, genetic carrier screening, chemical pathology, histopathology, and cytopathology; hematology, allergy, and immunology; serology and microbiology; and infectious molecular testing, cardiac testing services, functional pathology, veterinary pathology, and commercial drug and alcohol testing services. It offers its service to private and public hospitals. Australian Clinical Labs Limited was incorporated in 2020 and is headquartered in Clayton, Australia.

Australian Clinical Labs in the news

There are no recent company news

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and 6. Finder Group Privacy & Cookies Policy.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site